Physician profile
Brittany Smith
NPI 1184214256
$4,685.62
in general payments reported to CMS, 2019-2025
21 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $811 · 2022: $1,223 · 2023: $730 · 2024: $1,538 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.71 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $561.99 | 2021-2024 | Caplyta |
| Corium, LLC | $492.26 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $464.85 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $447.11 | 2022-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $288.14 | 2022-2024 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $283.94 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $196.09 | 2022-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $186.97 | 2021-2023 | Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $173.42 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $150.95 | 2021-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $138.41 | 2023-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $114.92 | 2022-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $105.00 | 2021-2024 | Trintellix |
| Lundbeck LLC | $103.87 | 2023-2024 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $76.10 | 2024 | |
| Sunovion Pharmaceuticals INC. | $54.22 | 2021-2022 | |
| Almatica Pharma LLC | $46.36 | 2022-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $16.19 | 2024 | Quviviq |
| Bausch Health US, LLC | $15.63 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.